Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.

@article{Sunde2006ExpressionPI,
  title={Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.},
  author={Jan Sunde and H. Donninger and Kongming Wu and Michael E. Johnson and R. Pestell and G. Rose and S. Mok and J. Brady and T. Bonome and M. Birrer},
  journal={Cancer research},
  year={2006},
  volume={66 17},
  pages={
          8404-12
        }
}
Ovarian cancer is resistant to the antiproliferative effects of transforming growth factor-beta (TGF-beta); however, the mechanism of this resistance remains unclear. We used oligonucleotide arrays to profile 37 undissected, 68 microdissected advanced-stage, and 14 microdissected early-stage papillary serous cancers to identify signaling pathways involved in ovarian cancer. A total of seven genes involved in TGF-beta signaling were identified that had altered expression >1.5-fold (P < 0.001) in… Expand
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.
TLDR
A TGF-β-inducible gene signature specific to CAFs in advanced high-grade serous ovarian tumors is identified, and it is shown how T GF-β stimulates ovarian cancer cell motility and invasion by upregulating the CAF-specific gene VCAN. Expand
Microenvironment and Immunology TGF-b Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
TGF-b has limited effects on ovarian cancer cells, but its contributions to ovarian tumor growth might be mediated through elements of the tumor microenvironment. In the present study, we tested theExpand
Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer
TLDR
Findings suggest that the reprogramming of the transcriptome that occurred as a consequence of the chromosome 3 transfer and tumor suppression affected molecular networks that are characteristic of ovarian carcinogenesis thus validating the novel ovarian cancer cell line model. Expand
TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy
TLDR
Targeting the TGF-β signaling pathway may be a novel therapeutic strategy in ovarian cancer because of its role in regulating numerous cellular processes including growth inhibition of ovarian surface epithelial cells. Expand
Smad4 mediates malignant behaviors of human ovarian carcinoma cell through the effect on expressions of E-cadherin, plasminogen activator inhibitor-1 and VEGF.
TLDR
Results from current work implicate Smad4 might suppress the invasion and metastasis of human ovarian tumor cells through a TGF-Beta/Smad-mediated pathway. Expand
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: A role in ovarian pathogenesis
TLDR
Results implicate SnoN levels in multiple roles during ovarian carcinogenesis: promoting cellular proliferation in ovarian cancer cells and as a positive mediator of cell cycle arrest and senescence in non‐transformed ovarian epithelial cells. Expand
Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression
TLDR
It is suggested that miR-205 functions as an oncogenic miRNA by directly binding to SMAD4 and PTEN, providing a novel target for the molecular treatment of ovarian cancer. Expand
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer
TLDR
The findings are suggestive for a possible tumor suppressor role of DOK1 in EOC; however its implication in enhanced EOC cell migration and proliferation restrain us to conclude thatDOK1 represents a true TSG in E OC. Expand
Overexpression of Evi‐1 oncoprotein represses TGF‐β signaling in colorectal cancer
TLDR
In conclusion, overexpression of Evi‐1 oncoprotein is identified as a novel mechanism by which a subset of human CRCs may escape TGF‐β regulation. Expand
Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer
TLDR
Dysregulated TGFβ/SMAD4 signaling may lead to epigenetic silencing of a putative tumor suppressor, RunX1T1, during ovarian carcinogenesis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling.
TLDR
Surprising, TGF-beta-induced Ski degradation was not observed in HOSE or CSOC, suggesting that Ski may not function as a T GF-beta/Smad corepressor in ovarian epithelial cells, and suggested that an alternate signaling pathway other than TGF, beta, or Smad may transmit TGF's cell cycle arrest in the ovarian epithelium. Expand
Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
TLDR
The results indicate that TGF-beta1 resistance and higher levels of MMP-2 production may be inherent properties of the ovarian cancer phenotype, and the mechanism of growth resistance is downstream of TbetaR-I phosphorylation. Expand
TGFβ-Induced Smad Signaling Remains Intact in Primary Human Ovarian Cancer Cells.
TLDR
Although OC1, CaOV3, and SkOV3 are not growth inhibited by TGFβ1, they can transmit the TGFα1 signal to turn on a transfected TGF β/Smad reporter gene, p3TP, and all cells up-regulate the endogenous T GFβ target genes Smad7 and PAI-1. Expand
Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
TLDR
The findings suggest that mutations in the TGF-beta RI and in its signal transduction pathway are likely responsible for human ovarian carcinogenesis. Expand
Inhibition of the antiproliferative effect of TGFβ by EGF in primary human ovarian cancer cells
TLDR
EGF decreases TGFβ-induced mRNA expression of the cell cycle regulator, p15INK4B, contributing to decreased sensitivity of OC cells to the antiproliferative effect of TGF β. Expand
Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration.
TLDR
A strong reduction of migratory and invasive properties was observed in these cells, suggesting that BMP4 promotes melanoma cell invasion and migration and therefore has an important role in the progression of malignant melanoma. Expand
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways
TLDR
The data generated in this study represent a comprehensive list of genes aberrantly expressed in serous papillary ovarian adenocarcinoma and may be useful for the identification of potentially new and novel markers and therapeutic targets for ovarian cancer. Expand
TGF-β signaling is disrupted in endometrioid-type endometrial carcinomas
TLDR
The data suggest that disturbances of the TGFβRII and SMAD4 expression as well as localization of SMADs may be important to the infiltration of the myometrial wall by the type I endometrial carcinomas. Expand
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
TLDR
The results indicate that the TGF-beta type I and type II receptor genes are selective targets of genetic inactivation in pancreatic and biliary cancers. Expand
Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas.
TLDR
It is shown that 33% of primary OCs harbor somatic changes in exons 2, 3, 4, and 6 of the TGF-beta receptor I (TbetaR-I) gene, suggesting that resistance to T GF-beta-mediated growth inhibition may frequently involve alterations of the R-I gene. Expand
...
1
2
3
4
5
...